Xcellerated T Cells: Phase I/II data

In a Phase I/II trial in 36 patients, 51% had a >=90% reduction in M-protein levels. Lymphocytes and T cells reached normal levels within a few days of treatment with Xcellerated T Cells. Data were pr...